Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

In the Spotlight

Kras, Pten, NF-κB, and Inflammation: Dangerous Liaisons

Paul J. Chiao and Jianhua Ling
Paul J. Chiao
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jianhua Ling
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/2159-8290.CD-11-0115 Published July 2011
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Ying and colleagues identify a novel function of Pten as a haploinsufficient tumor suppressor in human pancreatic cancer development. Genomic, genetic, and biochemical data reveal that Pten loss and Kras mutation cooperate to accelerate pancreatic cancer development by altering PI3K regulation to enhance NF-κB activation and upregulate downstream cytokine genes; this provides a protumorigenic and metastatic microenvironment. Cancer Discovery; 1(2); 103–5. ©2011 AACR.

Commentary on Ying et al., p. 158

In this issue of Cancer Discovery, Ying and colleagues (1) report that human genome analyses of pancreatic ductal adenocarcinoma (PDAC) and modeling PDAC in the mouse have identified Pten as a haploinsufficient tumor suppressor in metastatic PDAC development. Alterations in PI3K regulation caused by Pten loss and mutational activation of Kras enhances NF-κB activation and upregulation of downstream cytokine genes, which in turn promotes stromal activation and immune cell infiltration, shaping a pro-tumorigenic and pro-metastatic microenvironment.

Pancreatic cancer, which strikes 43,000 Americans annually (killing 36,800), is the fourth leading cause of adult cancer mortality in the United States (2). The 5-year survival rate has remained between 1% and 3% for the past 25 years (2). At the time of diagnosis, approximately 80% of PDAC patients present with locally advanced or metastatic therapy-resistant disease, and the median survival after diagnosis is <6 months (3). Even when stage I or II pancreatic cancer is localized to the pancreas and surgically removed, 70% of patients develop liver metastases in the absence of primary PDAC within 2 years of surgery (3). The onset of liver metastasis in the absence of primary PDAC is thought to be due to early neoplastic cell dissemination (3). Despite research advances, current chemotherapy and radiation therapy regimens are largely ineffective because most PDAC tumors are resistant to standard therapy and no useful drug targets have been identified. Hence, a better understanding of the molecular basis of PDAC inception and development is the key to identifying prevention strategies and therapeutic targets that will ultimately increase patient survival rates, one of the greatest challenges in current cancer research.

A genetic profile of PDAC is emerging on the basis of the most commonly detected mutations (Fig. 1; ref. 4, 5). For example, mutational Kras activation is an early event in pancreatic carcinogenesis and is detected in 80% to 95% of PDAC cases; inactivation of the p16/Ink4a and p53 tumor-suppressor genes is identified in approximately 50% and 75% of PDAC cases; and NF-κB is constitutively activated in nearly 70% of PDAC tumors, most PDAC cell lines (4, 6), and in many other tumor types as well (7). NF-κB activation in Ras-transformed cells is mediated through both the mitogen-activated protein kinase (MAPK) and PI3K pathways (7). NF-κB integrates pro-inflammatory signals and orchestrates anti-apoptotic responses (8); thus, NF-κB signaling has been implicated as a hallmark of cancer development (9). However, significant gaps still exist in our understanding of how such genetic alterations act in concert to induce NF-κB activation and PDAC development and progression. This question has now been answered in part by the findings of Ying and colleagues (1).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Progression model of pancreatic ductal adenocarcinoma. Progressive stages of pancreatic ductal adenocarcinoma from precursor lesions to cancer are based on references 4 and 5. The stages of onset and signature genetic and molecular alterations are indicated. Solid lines correspond to alterations that are detected at significant levels at the indicated stages. Broken lines correspond to alterations that may occur at the indicated stages but require further validation. PanIN, pancreatic intraepithelial neoplasia; PDAC, pancreatic ductal adenocarcinoma.

The Pten tumor suppressor gene is frequently deleted or mutated in human solid cancers. In genetically engineered mouse models of PDAC, mice harboring Pten deletions in the pancreas develop widespread ductal metaplasia and invasive pancreatic adenocarcinoma at a low frequency (10). In this report, Ying and colleagues (1) identified Pten as a haploinsufficient tumor suppressor that cooperated with Kras to induce PDAC in their Pdx1-cre; KrasG12D;PtenL/+ genetically engineered mouse model, which is consistent with an earlier report from the Wu group (11). Furthermore, Ying and colleagues (1) found frequent loss of at least one allele of the Pten gene in PDAC patient samples through high-resolution genome analyses of human PDAC; this result was supported by evidence that Pten heterozygosity was retained in the majority of mouse PDAC, suggesting Pten loss is a key genetic alteration in human PDAC progression (Fig. 1). In biochemical studies, the authors demonstrated that activation of the NF-κB pathway was associated with the expression of various cytokines and chemokines, which may play a role in recruiting inflammatory cell infiltrates into pancreatic tumors. The combined human PDAC genomic, mouse genetic, and functional studies have revealed that Pten functions as a haploinsufficient tumor suppressor in PDAC development. Moreover, frequent Pten loss and activation of the PI3K pathway, a common event in PDAC development, plays a key role in the progression of Kras-initiated PDAC in the Pdx1-Cre; KrasG12D; PtenL/+ PDAC mouse model by enhancing activation of the NF-κB signaling pathway, which in turn increases the expression of proinflammatory cytokines and chemokines that modulate the PDAC tumor microenvironment.

These new findings raise several important questions. What is the primum movens responsible for development of cancer-related inflammatory responses? What are the underlying mechanisms by which mutant Kras induces NF-κB activation? Is activation of PI3K the principal pathway that cooperates with mutant Kras to induce NF-κB activation? What is the expression profile of various NF-κB–dependant cytokines and chemokines in the epithelial cells expressing mutant Kras? How is the cooperation between tumor cells and their inflammatory surroundings orchestrated? Do the high levels of cytokines and chemokines in the tumor microenvironment further amplify the NF-κB pathway, reaching a crescendo in a feed-forward loop, in Pten-deficient cells to promote PDAC development? Can the NF-κB–activating pathways be targeted for preventive and therapeutic intervention for cancers harboring mutant Kras?

The findings by Ying and colleagues (1) suggest the need to obtain a more comprehensive mutational analysis of the PDAC genome and to evaluate the profiles of various signaling pathways, such as the PI3K and NF-κB pathways, in a large human PDAC sample set through the Cancer Genome Atlas projects. Kras mutation has been found in 80% to 95% of PDAC cases and has been shown to induce PDAC in mouse models (4, 12). However, targeting mutant Ras proteins directly with small-molecule inhibitors has thus far proven unsuccessful. Therefore, the discovery and inhibition of important signaling pathways that function downstream of mutant Ras may lead to the identification of novel and effective therapeutic targets (7). As a result of close cooperation between Pten deficiency and oncogenic Kras during PDAC development, the activation of the PI3K and NF-κB signaling pathways are such potential therapeutic targets. Thus, targeting multiple signaling pathways downstream of mutant Kras, including the PI3K, RalA, and MAPK pathways, may lead to effective treatment (7). For example, combined treatment of Kras-induced lung cancer in a genetically engineered mouse model with a dual pan-PI3K and mTOR inhibitor (NVP-BEZ235) and a mitogen-activated protein kinase kinase (MEK) inhibitor (ARRY-142886) resulted in marked synergy in inhibiting the lung cancer (13). It is also possible that directly inhibiting the key cytokine signaling pathways in PDAC harboring Pten deficiency and Kras mutation may represent additional opportunities for targeted therapy.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

  • ©2011 American Association for Cancer Research.

References

  1. 1.↵
    1. Ying H,
    2. Elpek KG,
    3. Vinjamoori A,
    4. Zimmerman SM,
    5. Chua GC,
    6. Yana H,
    7. et al
    . Pten is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-κB-cytokine network. Cancer Discovery 2011;1:158–69.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Jemal A,
    2. Siegel R,
    3. Xu J,
    4. Ward E
    . Cancer statistics, 2010. CA Cancer J Clin 2010;60:277–300.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Evans DB,
    2. Varadhachary GR,
    3. Crane CH,
    4. Sun CC,
    5. Lee JE,
    6. Pisters PW,
    7. et al
    . Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008;26:3496–502.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Hruban RH,
    2. Goggins M,
    3. Parsons J,
    4. Kern SE
    . Progression model for pancreatic cancer. Clin Cancer Res 2000;6:2969–72.
    OpenUrlFREE Full Text
  5. 5.↵
    1. Bardeesy N,
    2. DePinho RA
    . Pancreatic cancer biology and genetics. Nat Rev Cancer 2002;2:897–909.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Wang W,
    2. Abbruzzese JL,
    3. Evans DB,
    4. Larry L,
    5. Cleary KR,
    6. Chiao PJ
    . The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 1999;5:119–27.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Staudt LM
    . Oncogenic activation of NF-kappaB. Cold Spring Harb Perspect Biol 2010;2:a000109.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Fujioka S,
    2. Sclabas GM,
    3. Schmidt C,
    4. Niu J,
    5. Frederick WA,
    6. Dong QG,
    7. et al
    . Inhibition of constitutive NF-kappa B activity by I kappa B alpha M suppresses tumorigenesis. Oncogene 2003;22:1365–70.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Karin M,
    2. Greten FR
    . NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005;5:749–59.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Stanger BZ,
    2. Stiles B,
    3. Lauwers GY,
    4. Bardeesy N,
    5. Mendoza M,
    6. Wang Y,
    7. et al
    . Pten constrains centroacinar cell expansion and malignant transformation in the pancreas. Cancer Cell 2005;8:185–95.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Hill R,
    2. Calvopina JH,
    3. Kim C,
    4. Wang Y,
    5. Dawson DW,
    6. Donahue TR,
    7. et al
    . PTEN loss accelerates KrasG12D-induced pancreatic cancer development. Cancer Res 2010;70:7114–24.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Hingorani SR,
    2. Petricoin EF,
    3. Maitra A,
    4. Rajapakse V,
    5. King C,
    6. Jacobetz MA,
    7. et al
    . Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003;4:437–50.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Engelman JA,
    2. Chen L,
    3. Tan X,
    4. Crosby K,
    5. Guimaraes AR,
    6. Upadhyay R,
    7. et al
    . Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008;14:1351–6.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
Cancer Discovery: 1 (2)
July 2011
Volume 1, Issue 2
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Kras, Pten, NF-κB, and Inflammation: Dangerous Liaisons
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Kras, Pten, NF-κB, and Inflammation: Dangerous Liaisons
Paul J. Chiao and Jianhua Ling
Cancer Discov July 1 2011 (1) (2) 103-105; DOI: 10.1158/2159-8290.CD-11-0115

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Kras, Pten, NF-κB, and Inflammation: Dangerous Liaisons
Paul J. Chiao and Jianhua Ling
Cancer Discov July 1 2011 (1) (2) 103-105; DOI: 10.1158/2159-8290.CD-11-0115
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Disclosure of Potential Conflicts of Interest
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • At the Heart of Immune Checkpoint Inhibitor–Induced Immune Toxicity
  • Genetic Ancestry Correlations with Driver Mutations Suggest Complex Interactions between Somatic and Germline Variation in Cancer
  • Poorer Clinical Outcomes for Black Patients with AML: A Wake-Up Call for Better Data and Greater Understanding of Cancer Outcomes in All Ethnic Groups
Show more In the Spotlight
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement